CoreWeave Seals the Deal to Buy Core Scientific. Should You Buy CRWV Stock Here?

CoreWeave (CRWV) confirmed its ~$9 billion acquisition of Core Scientific (CORZ), a strategic move to secure critical data center infrastructure, eliminate $10 billion in future lease obligations, and achieve an estimated $500 million in annual run-rate cost savings by 2027. Despite these operational benefits and access to 1.3 GW of power capacity, CRWV shares closed lower, as analysts, including Macquarie, maintain a 'Neutral' rating with significant downside targets (up to 59%), citing the company's high 28x price-to-sales valuation which they believe already accounts for any potential earnings accretion, reflecting broader Wall Street skepticism.

Analysis

CoreWeave (CRWV) has confirmed its acquisition of Core Scientific (CORZ) for approximately $9 billion, a strategic move that triggered a negative reaction in its share price despite the stock's 220% gain since its IPO. The transaction, expected to close in Q4 2025, is designed to vertically integrate critical data center infrastructure, providing CRWV with 1.3 GW of power capacity. Management anticipates this will eliminate over $10 billion in future lease obligations and generate an estimated $500 million in annual run-rate cost savings by 2027. However, the market's cautious sentiment, reflected in a -0.5 score for CRWV, is heavily influenced by analyst concerns over valuation. Macquarie reiterated a "Neutral" rating with a $65 price target, implying 59% downside, arguing that the deal's potential 5% EPS accretion is already priced into the stock's elevated price-to-sales ratio of over 28x. This skepticism is shared across Wall Street, with a consensus mean target price of $82 suggesting nearly 50% potential downside from current levels, creating a stark contrast between the deal's long-term strategic logic and immediate valuation-based headwinds.

Key Decisions for Investors

• Investors should weigh the significant valuation risk highlighted by a 28x price-to-sales ratio and analyst consensus price targets suggesting downside of nearly 50%.
• Consider the transaction's long-term strategic value, including control over 1.3 GW of power and $500 million in synergies, against the immediate negative market sentiment and potential for a valuation-driven stock correction.
• Monitor the acquisition's progress toward regulatory and shareholder approvals, as any delays or obstacles ahead of the Q4 2025 closing could introduce further volatility to CRWV's share price.